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Food contains bioactive compounds that may prevent changes in gut microbiota associated with 
Westernized diets. The aim of this study is to explore the possible additive effects of d-fagomine and ω-3 
PUFAs (EPA/DHA 1:1) on gut microbiota and related risk factors during early stages in the development 
of fat-induced pre-diabetes. Male Sprague Dawley (SD) rats were fed a standard diet, or a high-fat (HF) 
diet supplemented with d-fagomine, EPA/DHA 1:1, a combination of both, or neither, for 24 weeks. 
The variables measured were fasting glucose and glucose tolerance, plasma insulin, liver inflammation, 
fecal/cecal gut bacterial subgroups and short-chain fatty acids (SCFAs). The animals supplemented 
with d-fagomine alone and in combination with ω-3 PUFAs accumulated less fat than those in the non-
supplemented HF group and those given only ω-3 PUFAs. The combined supplements attenuated the 
high-fat-induced incipient insulin resistance (IR), and liver inflammation, while increasing the cecal 
content, the Bacteroidetes:Firmicutes ratio and the populations of Bifidobacteriales. The functional 
effects of the combination of d-fagomine and EPA/DHA 1:1 against gut dysbiosis and the very early 
metabolic alterations induced by a high-fat diet are mainly those of d-fagomine complemented by the 
anti-inflammatory action of ω-3 PUFAs.
There is mounting evidence that diet affects homeostasis by modifying the gut microbial populations in both 
rodents and humans1–3. Early insulin resistance (IR) and impaired glucose tolerance (IGT), which appear in 
the first stage of diet-induced type 2 diabetes4, might be triggered by intestinal barrier alterations induced by 
unbalanced microbiota (dysbiosis)5. Lipopolysaccharides (LPS: a component of the cell wall of Gram-negative 
bacteria), short-chain fatty acids (SCFAs: end products of the fermentation of dietary fiber by bacteria) and bile 
acids are possible mediators linking gut bacteria to IR and adipose tissue function5. Dietary changes can rapidly 
modify gut microbial composition1,6. Fat- or carbohydrate-restricted diets increase the populations of the order 
Bacteroidetes while reducing body weight7. At the genus level, a high intake of fat and protein is positively associ-
ated with Bacteroides; whereas a high fiber intake is related to increased levels of Prevotella8,9. Food components 
such as prebiotic fiber may prevent changes in gut microbiota associated with obesity and metabolic disorders2.
The iminosugar d-fagomine (1,2-dideoxynojirimycin) is a stable cyclic carbohydrate analog with a nitrogen 
atom in place of the oxygen atom within the cycle that was first isolated from buckwheat seeds (Fagopyrum 
esculentum)10. d-Fagomine reduces post-prandial blood glucose concentration in sucrose/starch loading tests in 
healthy rats through the inhibition of intestinal disaccharidases11 and it attenuates high-fat-induced low-grade 
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inflammation and IGT in rats12,13. d-Fagomine also promotes gut microbial diversity by increasing the relative 
populations of Bacteroidetes in healthy rats, while also mitigating the age-related reduction in the populations of 
the putatively beneficial bacteria Lactobacillus and Bifidobacterium14 and stabilizing the populations of Prevotella 
in the intestinal tract of healthy rats (Hereu, Nutrients, accepted).
Eicosapentaenoic acid (EPA, 20:5, n-3) and docosahexaenoic acid (DHA, 22:6, n-3) are the major ω-3 PUFAs in 
fish oil. EPA and DHA reduce elevated plasma cholesterol and triglycerides, oxidative stress (OS), and high blood 
pressure, which are risk factors for cardiovascular diseases15 and other pathologies that involve inflammation16. The 
possible contribution of changes in gut microbiota to the anti-inflammatory activity of ω-3 PUFAs is poorly docu-
mented. It has been shown that EPA and DHA increase the populations of putatively beneficial gut Lactobacillus and 
Bifidobacteria in mice fed a high-fat diet17,18. When combined with proanthocyanidins or d-fagomine, EPA/DHA 
1:1 helps to stabilize the populations of Bifidobacteriales and Lactobacilliales in healthy rats19.
The aim of this study is to explore the possible complementary or additive effects of d-fagomine and ω-3 
PUFAs (EPA/DHA 1:1) on gut microbiota and risk factors for diabetes during early stages in the development of 
fat-induced pre-diabetes in rats.
Methods
Animals, experimental design and sample collection. Male Sprague Dawley (SD) rats from Envigo 
(Indianapolis, IN, USA), aged 8–9 weeks were used. As we wanted to detect early effects of the supplementa-
tions, SD rats were preferred over other strains, such as Wistar rats, because they take longer to develop IGT20. 
The rats (n = 45) were housed (n = 3 per cage) under controlled conditions of humidity (60%), and temperature 
(22 ± 2 °C) with a 12 h light-12 h dark cycle. They were randomly divided into 5 groups (n = 9 per group): the 
control group (STD), fed a standard diet (2014 Teklad Global 14% Protein Diet from Envigo); the high-fat group 
(HF), fed only a high-fat diet (TD.08811 45% kcal fat diet from Envigo) with no supplementation; a group fed the 
high-fat diet supplemented with d-fagomine (Envigo custom designed, manufactured by Mucedola srl; Settimo 
Milanese, Italy) (HF + FG group); a group fed the high-fat diet supplemented with ω-3 PUFAs (HF + ω-3 group); 
and a group fed the high-fat diet supplemented with both d-fagomine and ω-3 PUFAs (HF + FG + ω-3 group). 
d-Fagomine (>98%) manufactured by Bioglane SLNE (Barcelona, Spain) was generously provided by Taihua 
Shouyue (HK) International Co. Ltd. (Hong Kong, China). It was included in the feed at a proportion of 0.96 g/kg 
feed, as in previous studies11,13. ω-3 PUFAs (EPA/DHA 1:1) were obtained by mixing the appropriate quantities of 
the commercial fish oils AFAMPES 121 EPA (AFAMSA, Vigo, Spain) and EnerZona Omega 3 RX (Milan, Italy). 
ω-3 PUFAs were administered by oral gavage using a gastric probe once a week at a dose of 0.8 mL oil per kg body 
weight. The dose and EPA/DHA proportions used were previously determined21. To compensate for the stress 
of probing and the excess of calories from fish oil in the HF + ω-3 and HF + FG + ω-3 groups, the animals in the 
groups STD, HF and HF + FG were administered soybean oil at the same dose at the same time. The major fatty 
acids in soybean oil triglycerides are polyunsaturated alpha-linolenic acid (7%) and linoleic acid (LA, 51%), mon-
ounsaturated oleic acid (23%) and the saturated stearic and palmitic acids (4% and 11%, respectively)22. All the 
groups were fed ad libitum with free access to water. The composition of the diets is provided as Supplementary 
Material, Table 1.
Feed consumption was monitored daily and body weight was measured weekly throughout the experiment. 
Energy intake was calculated as estimates of metabolizable energy based on the Atwater factors, assigning 4 kcal/g 
protein, 9 kcal/g fat, and 4 kcal/g available carbohydrate.
After overnight fasting, blood samples were collected from the saphenous vein at weeks 9, 14 and 23 of the 
experiment. Plasma was separated by centrifugation and stored at −80 °C until analysis. At week 21, urine was 
collected by placing the rats in metabolic cages; while after week 23, fecal samples were collected by abdominal 
massage.
At the end of the experiment (week 24), the rats were fasted overnight and anesthetized intraperitoneally 
with ketamine and xylazine (80 and 10 mg per kg body weight, respectively) and then killed by exsanguination. 
Perigonadal fat, liver and cecum were removed, weighed and stored at −80 °C. One portion of the liver was fixed 
in 4% formalin for histological analysis.
All the procedures strictly adhered to the European Union guidelines for the care and management of labora-
tory animals, and were licensed by the regional Catalan authorities (reference no. DAAM7921), as approved by 
the Spanish CSIC Subcommittee of Bioethical Issues.
Glycemic status. Fasting blood glucose and plasma insulin levels were measured after weeks 9, 14 and 
23 in fasted animals. Blood glucose concentration was measured by the enzyme electrode method, using an 
Ascensia ELITE XL blood glucose meter (Bayer Consumer Care; Basel, Switzerland). Plasma insulin levels 
were measured using the rat/mouse insulin ELISA kit from Millipore Corporation (Billerica, MA, USA). The 
HOMA (Homeostatic Assessment Model) index was calculated as fasting insulin (µU/mL) × fasting glucose 
(mmol/L)/22.523. Insulin units (IU) were calculated using the conversion 1 IU = 0.0347 mg insulin.
The oral glucose tolerance test (OGTT) was performed at week 20 on fasted animals. A solution of glucose 
(1 g/kg body weight) was administered by oral gavage, and blood glucose concentration was measured 15, 30, 45, 
60, 90 and 120 min after glucose intake by the enzyme electrode method.
Plasma leptin levels were measured using MILLIPLEX xMAP multiplex technology on a Luminex xMAP 
instrument (Millipore, Austin, TX, USA) at week 23. MILLIPLEX Analyst 5.1 (VigeneTech; Carlisle, PA, USA) 
software was used for data analysis.
Isoprostanes in urine. F2t-isoprostanes (F2t-IsoPs) were determined in urine samples by LC/ESI-MS/MS 
following a previously reported procedure24 with some modifications. Urine samples (500 µL) were acidified, 
β-glucuronidase (90 U/mL) (Sigma; Saint Louis, MO, USA) was added, and the mixtures were incubated for 2 h 
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at 37 °C. After the addition of the internal standard [2H4]15-F2t-IsoP (Cayman; Ann Arbor, MO, USA) (100 µL, 
10 µg/L), F2t-IsoPs were purified by SPE in a C18 Sep-Pak cartridge (Waters, Mildford, MA, USA). F2t-IsoPs were 
analyzed using an Agilent 1260 chromatograph fitted with a Mediterranea Sea 18 column (10 cm × 2.1 mm id., 
2.2 µm particle size) (Teknokroma; Barcelona, Spain) coupled to a 4000 QTRAP mass spectrometer (Applied 
Biosystems; Foster City, CA, USA). The instrument was operated in the negative ion mode with a Turbo V source 
to obtain MS/MS data. Separation was achieved with a binary system consisting of 0.1% aqueous formic acid 
[A] and formic acid in acetonitrile [B], at 40 °C, with an increasing linear gradient (v/v) of [B]: 0 min, 10% B; 
7 min, 50% B; 7.1 min, 100% B; 8 min, 100% B; 8.1 min, 10% B; and 10 min, 10% B, at a flow rate of 700 µL/min. 
F2t-IsoPs were detected by MS/MS multiple reaction monitoring. Calibration curves were prepared using seven 
matrix-matched standards covering the working concentration range. The LOQ was 0.4 µg/L for 15-F2t-IsoP 
and 2 µg/L for 5-F2t-IsoP. The results were expressed as nanograms per milligram of creatinine, to correct for 
urine dilution. Creatinine levels in urine were determined via a colorimetric method using a commercial kit 
(Creatinine-J, Spinreact; Girona, Spain) by measuring absorbance at 492 nm.
Subpopulations of gut microbiota. The relative populations of selected bacterial phyla, orders and genera 
were estimated in fecal and cecal DNA by quantitative real-time polymerase chain reaction (qRT-PCR). DNA was 
extracted from fecal and cecal samples using a QIAamp® DNA Stool Mini Kit from QIAGEN (Hilden, Germany). 
Its concentration was quantified using a Nanodrop 8000 Spectrophotometer (ThermoScientific; Waltham, 
MA, USA) and all DNA samples were diluted to 20 ng/µL. The qRT-PCR experiments were carried out using 
a LightCycler® 480 II (Roche, Basel, Switzerland) in triplicate. Each qRT-PCR well contained a total of 20 µL: 
DNA (2 µL) and a master mix (18 µL) made of 2X SYBR (10 µL), the corresponding forward and reverse primer 
(1 µL each), and water (6 µL) purified using a Milli-Q system (Millipore Corporation; Billerica, MA, USA). All 
the reactions were paralleled by analysis of a non-template control (water) and a positive control (Supplementary 
Material, Table 2) from DSMZ (Braunschweig, Germany). The qRT-PCR cycling conditions were: 10 s at 95 °C, 
then 45 cycles of 5 s at 95 °C, 30 s at the primer-specific annealing temperature (Supplementary Material, Table 2), 
and 30 s at 72 °C (extension). The specificity of the qRT-PCR reactions was assessed by melting curve analysis 
which consisted of heating to 95 °C and maintaining this temperature for 2 s, then cooling to 65 °C and maintain-
ing this temperature for 15 s, and running a temperature gradient from 65 °C to 95 °C at a rate of 0.11 °C/s, with 
five fluorescence recordings per °C. The relative DNA abundances for each bacterial subgroup were calculated 
from the second derivative maximum of their respective amplification curves (Cp, calculated in triplicate) by 
considering Cp values to be proportional to the dual logarithm of the inverse of the specific DNA concentration, 
following the equation: [DNAa]/[DNAb] = 2Cpb-Cpa 25. Amounts of total bacteria were normalized as 16S rRNA 
gene copies per mg of wet feces (copies/mg).
Short-chain fatty acids. SCFAs were analyzed in feces and in cecal content by gas chromatography 
(GC) using a previously described method26 with some modifications. Briefly, the samples were freeze-dried 
and weighed (~50 mg dry matter) and a solution (1.5 mL) containing the internal standard 2-ethylbutiric acid 
(6.67 mg/L) and oxalic acid (2.97 g/L) in acetonitrile/water 3:7 was added. Then, SCFAs were extracted for 10 min 
using a rotating mixer. The suspension was centrifuged (5 min, 12,880 g) in a 5810R centrifuge (Eppendorf; 
Hamburg, Germany) and the supernatant passed through a 0.45 µm nylon filter. An aliquot of the supernatant 
(0.7 mL) was diluted to 1 mL with acetonitrile/water 3:7. SCFAs were analyzed using a Trace 2000 gas chromato-
graph coupled to a flame ionization detector (ThermoFinnigan; Waltham, MA, USA) equipped with an Innowax 
30 m × 530 µm × 1 µm capillary column (Agilent; Santa Clara, CA, USA). Chrom-Card software was used for 
data processing. Helium was used as the carrier gas with a linear velocity of 5 mL/min. GC oven temperature was 
programmed as follows: 80 °C (hold 1 min) to 120 °C at 15 °C/min (hold 4 min) to 130 °C at 5 °C/min (hold 4 min) 
to 235 °C at 8 °C/min (hold 4 min). Flame ionization detection (FID) was performed at a base temperature of 
240 °C. Calibration curves were prepared using seven matrix-matched standards covering the working concen-
tration range. The precision (RSD <15%) and recovery (>70%) of the method were adequate and both inter- and 
intra-day reproducible.
Liver histology. Fixed livers were dehydrated in alcohol and embedded in paraffin (Panreac Quimica SLU; 
Barcelona, Spain), then cut into 3 µm-thick slices, using a steel knife mounted in a microtome (HM 355S Rotary 
Microtome, Thermo Fisher Scientific; Waltham, MA, USA). Sections were stained with hematoxylin (hematox-
ylin solution modified in accordance with Gill III for microscopy, Merck KGaA; Darmstadt, Germany)/eosin 
(Pharmacy Service of Puerta del Mar Hospital; Cadiz, Spain) then viewed under a light microscope (NIKON 
Eclipse 80i, NIKON Corporation; Minato, Japan). Variables were graded following the method described by 
Taltavull et al.27 using observation of the entire field of the tissue preparations: steatosis, 0 (absence) or 1 (pres-
ence); and lobular inflammation, 0 (absence), 1 (1–2 foci), 2 (2–4 foci), or 3 (>4 foci).
Statistical analysis. All data manipulation and statistical analysis was performed using GraphPad Prism 5 
(GraphPad Software; San Diego, CA, USA). The results are expressed as means with their standard errors (SEM). 
The normal distributions and heterogeneity of the data were evaluated, and statistical significance was deter-
mined by one-way ANOVA and the Tukey multiple-comparisons test or by two-way ANOVA. Differences were 
considered significant when P ≤ 0.05 and were considered to indicate a tendency when 0.05 < P ≤ 0.1.
Results
Feed and energy intakes, body weight, perigonadal fat, plasma leptin and urine F2t-isoprostanes. 
All the rats fed the high-fat diet consumed less feed but more energy than those in the STD group (Table 1), whether 
they were supplemented with d-fagomine and/or ω-3 PUFAs or not.
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At the beginning of the study, the mean body weight was 323.9 ± 6.3 g (Supplementary Material, Fig. 1). At the 
end of the study (after 24 weeks) the rats in the HF group showed a tendency (P = 0.07) to gain more weight than 
the STD group (Table 1). There were no significant differences between the supplemented groups and either the 
STD or the HF group. The body weight curve corresponding to the group supplemented with both d-fagomine 
and ω-3 PUFAs was similar to that of the STD group without reaching statistically significant differences with that 
of the HF group (Supplementary Material, Fig. 1B).
The HF group and the rats supplemented only with ω-3 PUFAs showed significantly higher (P < 0.05) perigo-
nadal fat deposition than the STD group; while the groups supplemented with d-fagomine presented a level of 
perigonadal fat similar to the STD group (Fig. 1B).
Plasma leptin concentration (Fig. 1C) was higher (P < 0.01) in the HF group than in the STD group; all the 
supplementations resulted in leptin levels statistically similar to those of the STD group.
The animals fed the high-fat diet supplemented with ω-3 PUFAs had significantly (P < 0.05) lower concentra-
tions of total urine F2t-IsoPs (5-F2t-IsoP plus 15-F2t-IsoP: markers of systemic OS) after 21 weeks, than rats in the 
STD group (Fig. 1D). The levels of F2t-IsoPs were similar among the supplemented groups.
Glycemic status. Plasma fasting glucose and insulin were measured at weeks 9, 14 and 23 (Fig. 2) of the 
study. Fasting glucose levels were below 80 mg/dL in all the groups at all times. Fasting glucose levels in the HF 
groups were higher (P < 0.05) than those in the STD group after 14 weeks of intervention (Fig. 2D,G), except in 
the group supplemented with both d-fagomine and ω-3 PUFAs; while plasma insulin was significantly elevated 
in the HF group compared to the STD group already at week 9 (Fig. 2B) and remained so up to the end of the 
study (Fig. 2H). The group supplemented only with d-fagomine presented insulin levels similar to the STD group 
throughout the experiment (Fig. 2B,E,H). The rats supplemented with ω-3 PUFAs (HF + ω-3 and HF + FG + ω-3 
groups) showed plasma insulin levels similar to those in the STD group only at the end of the study (Fig. 2H).
HOMA-IR is an indicator of IR that accounts for the levels of fasting plasma glucose and insulin levels. 
HOMA-IR increased in all the HF groups (P < 0.05 vs STD group) except in the group supplemented with 
d-fagomine, as early as week 9 and for the entire experiment (Fig. 2C). At the end of the study (week 23), there 
were no significant differences in HOMA-IR between the groups supplemented with d-fagomine (HF + FG and 
HF + FG + ω-3) and the other groups (Fig. 2I).
The OGTT was performed at week 20, near the end of the experiment (Supplementary Material, Fig. 2). 
Although there were no significant differences in the area under the curve between groups, the response curves 
corresponding to the animals given the combination of d-fagomine and ω-3 PUFAs was superimposable to that 
generated with the control animals (Supplementary Material, Fig. 2C).
Subpopulations of gut microbiota. The proportions of the major bacterial phyla (Bacteroidetes and 
Firmicutes), selected orders (Lactobacilliales, Bifidobacteriales and Enterobacteriales) and genera (Prevotella and 
Bacteroides) were estimated in fecal and cecal DNA (Figs 3 and 4, respectively) at the end of the study (week 
23–24).
In fecal samples, the proportion of Bacteroidetes (Fig. 3A) significantly (P < 0.01) decreased and the propor-
tion of Firmicutes (Fig. 3B) significantly (P < 0.001) increased in rats from groups HF and HF + ω-3, with respect 
to the STD group. The proportion of Bacteroidetes and Firmicutes in animals supplemented with d-fagomine 
(the HF + FG and HF + FG + ω-3 groups) was similar to that in animals in the STD group. The percentage of 
Lactobacilliales (Fig. 3D) was significantly (P < 0.05) higher in the HF + FG group than in all other groups; while 
the population of Bifidobacteriales (Fig. 3E) was significantly (P < 0.05) higher in both groups supplemented 
with d-fagomine (HF + FG and HF + FG + ω-3) compared to the other groups. Only the HF group presented a 
proportion of Enterobacteriales significantly (P < 0.05) higher than that in the STD group (Fig. 3F). Significant 
differences between groups in the relative populations of the genera Prevotella and Bacteroides were detected. 
The proportions of Prevotella (Fig. 3G) and Bacteroides (Fig. 3H) were significantly (P < 0.05) lower in all HF 
groups with respect to the STD group. The supplementation with d-fagomine (the HF + FG and HF + FG + ω-3 
groups) partially counteracted the reduction in the relative populations of Prevotella (Fig. 3G). The populations 
of Bacteriodes was significantly affected only in the doubly supplemented rats (Fig. 3H).
In cecal samples, the proportion of Bacteroidetes significantly (P < 0.01) increased in the group of ani-
mals supplemented with both d-fagomine and ω-3 PUFAs, with respect to all the other groups (Fig. 4A). The 
STD HF HF + FG HF + ω-3 HF + FG + ω-3
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Feed intake
(g/day/100 g body weight) 4.6 0.5 3.3*** 0.1 3.0*** 0.1 3.2*** 0.1 3.4*** 0.1
Energy intake£
(kcal/day/100 g body weight) 13.3 1.4 15.3*** 0.5 15.0*** 0.1 15.7*** 0.5 16.1*** 0.1
Body weight gain (%) 67.3 4.1 78.9† 4.6 74.2 2.2 76.4 5.7 71.5ϕ 3.3
Table 1. Feed and energy intakes, and final body weight gain of SD rats fed a high-fat diet supplemented, 
or not, with d-fagomine, ω-3 PUFAs or a combination of both, for 24 weeks. £Energy intake is estimated as 
metabolizable energy based on Atwater factors, which assign 4 kcal/g protein, 9 kcal/g fat, and 4 kcal/g available 
carbohydrates. Data are presented as means with their standard errors; n = 9 per group. Comparisons were 
conducted using one-way ANOVA and Tukey’s multiple comparisons test. ***P < 0.001 vs STD (†P = 0.07 vs 
STD, ϕP = 0.08 vs HF).
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proportion of Firmicutes significantly increased in the HF group and those groups given single supplementations 
with respect to the STD group, while the group supplemented with both d-fagomine and ω-3 PUFAs showed 
values similar to the STD group (Fig. 4B). The highest Bacteroidetes/Firmicutes ratio resulted from the com-
bined supplementation (the HF + FG + ω-3 group, Fig. 4C). The percentage of Lactobacilliales (Fig. 4D) was 
significantly (P < 0.01) higher in the HF + FG group than in the HF and HF + ω-3 groups; while the population 
of Bifidobacteriales (Fig. 4E) in both d-fagomine-supplemented groups was not significantly different from that 
in the STD group. The proportion Bacteroides was significantly (P < 0.05) higher in animals supplemented with 
both d-fagomine and ω-3 PUFAs than in those given the high-fat diet (Fig. 4H).
Animals in the HF group as well as those given single supplementation (HF + FG and HF + ω-3 groups) had 
significantly lower cecum content than those in the STD group. The group supplemented with both d-fagomine 
and EPA/DHA 1:1 had significantly higher (P < 0.01) cecum content than the HF group, and it was statistically 
similar to that of the STD group (Fig. 4I).
Short-chain fatty acids. SCFAs were determined in feces (Table 2) and in the cecal content (Table 3) at the 
end of the study (week 23–24).
In fecal samples, the concentration of total SCFAs and the major component (acetic acid) was significantly 
reduced (P < 0.05) in all HF groups except the group supplemented only with d-fagomine.
Figure 1. Final body weight (A) perigonadal fat (B) plasma leptin (C) and urine F2t-IsoPs (D) of SD rats fed 
a standard (STD), high-fat (HF), high-fat supplemented with d-fagomine (HF + FG), high-fat supplemented 
with EPA/DHA (1:1) (HF + ω-3) or high-fat supplemented with both d-fagomine and EPA/DHA (1:1) 
(HF + FG + ω-3) diet for 24 weeks (A–C) or 21 weeks. (D) Data are presented as means with their standard 
errors. Comparisons were performed using one-way ANOVA followed by Tukey’s post-hoc test. *P < 0.05, 
**P < 0.01 vs STD.
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In cecal samples, the concentration of acetic acid was significantly reduced (P < 0.001) in all HF groups; while 
the concentration of butyric acid was significantly higher (P < 0.01) in all these groups than in the STD group. 
The levels of isobutyric acid were significantly reduced (P < 0.05) in the HF group without supplementation and 
the group supplemented only with ω-3, but not in the 2 d-fagomine supplemented groups. The concentration 
of isovaleric acid was significantly higher (P < 0.05) in the HF + FG group than in the HF group; while levels of 
valeric acid were higher (P < 0.001) in all the supplemented groups (HF + FG, HF + ω-3 and HF + FG + ω-3) 
than in the STD group.
Liver histology. Steatosis and lobular inflammation were determined by histology (Fig. 5). The livers of 
animals supplemented with d-fagomine presented higher (P < 0.05) steatosis than those from the STD group 
Figure 2. Plasma levels of fasting glucose (A,D,G) insulin (B,E,H) and calculated HOMA-IR (C,F,I) in 
SD rats fed a standard (STD), high-fat (HF), high-fat supplemented with d-fagomine (HF + FG), high-fat 
supplemented with EPA/DHA (1:1) (HF + ω-3) or high-fat supplemented with both d-fagomine and EPA/DHA 
(1:1) (HF + FG + ω-3) diet after 9 (A–C), 14 (D,E,G) and 23 weeks. (H–J) Data are presented as means with 
their standard errors. Comparisons were performed using one-way ANOVA followed by Tukey’s post-hoc test. 
*P < 0.05, **P < 0.01, ***P < 0.001 vs STD.
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(Fig. 5A) and the livers from animals supplemented with both d-fagomine and ω-3 PUFAs presented higher 
(P < 0.05) steatosis than those from rats in the HF and HF + ω-3 groups. Lobular inflammation of animals in the 
HF and HF + FG groups was higher (P < 0.05) than for those in the STD group (Fig. 5B).
Discussion
The present study examines the effects of the combination of d-fagomine and ω-3 PUFAs (EPA/DHA 1:1) on SD 
rats at a very early stage in the development of fat-induced pre-diabetes. SD rats aged 8–9 weeks and fed a high-fat 
diet (HF group) developed incipient IR as assessed by plasma insulin levels (P < 0.01 vs. STD group) HOMA-IR 
(P < 0.05 vs. STD group) (Fig. 2). They showed significantly high perigonadal fat accumulation (P < 0.05 vs. 
the STD group) without reaching statistically significant differences in weight gain (P = 0.07 vs. STD group) 
over a period of 24 weeks. These changes are consistent with a physiological compensation for reduced insulin 
Figure 3. Relative gut microbial subpopulations in fecal samples from SD rats fed a standard (STD), high-
fat (HF), high-fat supplemented with d-fagomine (HF + FG), high-fat supplemented with EPA/DHA (1:1) 
(HF + ω-3) or high-fat supplemented with both d-fagomine and EPA/DHA (1:1) (HF + FG + ω-3) diet 
after 23 weeks. Bacteroidetes (A) Firmicutes (B) Bacteroidetes:Firmicutes ratio (C) Lactobacilliales (D) 
Bifidobacteriales (E) Enterobacteriales (F) Prevotella (G) and Bacteroides. (H) Data are presented as means 
with their standard error. Comparisons were made using one-way ANOVA followed by Tukey’s post-hoc test. 
*P < 0.05, **P < 0.01, ***P < 0.001 vs STD; #P < 0.05, ##P < 0.01, ###P < 0.001 vs HF; δP < 0.05 vs HF + FG; and 
†P < 0.05, ††P < 0.01, †††P < 0.001, vs HF + ω-3.
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sensitivity, the first stage in the progression to diabetes proposed for humans4. SD rats did not develop signifi-
cant IGT (Supplementary Material, Fig. 2). The metabolic effects of the high-fat diet are less evident than those 
we reported for Wistar Kyoto (WKY) rats13. WKY rats fed a high-fat diet significantly (P < 0.001) gained more 
weight than those fed a STD diet over the same period of time13 and they presented IGT with postprandial blood 
glucose levels around 150 mg/dL, already at week 13 of the intervention13; while here, postprandial blood glucose 
concentration in SD rats fed a high-fat diet was lower than 120 mg/dL even at week 20 (Supplementary Material, 
Fig. 2). These observations coincide with the results published by other authors showing that: (i) even though SD 
rats gain more weight than Wistar rats, the differences between the STD group and the high-fat group are lower in 
SD rats; and (ii) SD rats fed a high-fat diet develop IGT later than Wistar rats do20. Therefore, differences in weight 
gain and effects on glucose metabolism are harder to detect in SD rats than in Wistar or WKY rats.
Figure 4. Relative gut microbial subpopulations in cecal samples of SD rats fed a standard (STD), high-fat (HF), 
high-fat supplemented with d-fagomine (HF + FG), high-fat supplemented with EPA/DHA (1:1) (HF + ω-3) 
or high-fat supplemented with both d-fagomine and EPA/DHA (1:1) (HF + FG + ω-3) diet after 24 weeks. 
Bacteroidetes (A) Firmicutes (B) Bacteroidetes:Firmicutes ratio (C) Lactobacilliales (D) Bifidobacteriales 
(E) Enterobacteriales (F) Prevotella (G) and Bacteroides (H) Cecum weight (I). Data are presented as means 
with their standard error. Comparisons were made using one-way ANOVA followed by Tukey’s post-hoc test. 
*P < 0.05, **P < 0.01, ***P < 0.001 vs STD; ##P < 0.01, ###P < 0.001 vs HF; δδP < 0.01 vs HF + FG; and †P < 0.05, 
††P < 0.01, †††P < 0.001 vs HF + ω-3.
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d-Fagomine showed some effect on IR both when given alone and combined with EPA/DHA 1:1 as the val-
ues of HOMA-IR were statistically similar to those in the controls (STD group) (Fig. 2). The groups supple-
mented with d-fagomine also presented a level of perigonadal fat statistically similar to the STD group (Fig. 1B). 
STD HF HF + FG HF + ω-3 HF + FG + ω-3
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Acetic acid 115 13 77** 3 91 11 85* 6 80** 4
Propionic acid 13.4 0.9 5.7*** 0.5 8.6* 1.6 4.7*** 0.9 4.0*** 0.8
Isobutyric acid 2.7 0.2 1.0*** 0.2 1.4*** 0.2 1.3*** 0.3 1.6** 0.7
Butyric acid 17 2 8** 1 7*** 2 7*** 1 6*** 2
Isovaleric acid 1.7 0.2 0.6*** 0.1 0.9* 0.2 0.4*** 0.3 0.5*** 0.3
Valeric acid 1.4 0.1 0.8** 0.0 0.9* 0.1 0.6*** 0.3 0.6*** 0.3
TOTAL SCFAs 152 9 94** 3 110 14 99* 2 93** 2
Table 2. Fecal short-chain fatty acids (SCFAs) after week 23 of the study. Data are presented as means with their 
standard errors; n = 9 per group. SCFA amounts are given in millimoles per kilogram feces. Comparisons were 
conducted using one-way ANOVA and Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001 
vs STD.
STD HF HF + FG HF + ω-3 HF + FG + ω-3
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Acetic acid 160 18 75*** 9 84*** 10 89*** 10 74*** 8
Propionic acid 32.4 3.7 25.5 2.6 32.4 3.2 32.4 4.2 34.0 5.4
Isobutyric acid 3.7 0.3 2.1* 0.1 3.4 0.3 2.6* 0.2 3.5 0.4
Butyric acid 12 1 25** 2 25** 3 33*** 3 27*** 3
Isovaleric acid 3.2 0.3 1.9 0.2 3.6& 0.4 2.7 0.4 3.2 0.6
Valeric acid 1.9 0.3 3.4 0.2 4.6*** 0.4 4.7*** 0.4 4.4*** 0.4
TOTAL SCFAs 213 23 133* 13 153 14 164 17 147 16
Table 3. Cecal short-chain fatty acids (SCFAs) at the end of the study (24 weeks). Data are presented as means 
with their standard errors; n = 9 per group. SCFA amounts are given in millimoles per kilogram cecum. 
Comparisons were conducted using one-way ANOVA and Tukey’s multiple comparisons test. *P < 0.05, 
**P < 0.01, ***P < 0.001 vs STD; and &P < 0.05 vs HF.
Figure 5. Liver histology. Estimation of variables in SD rats fed a standard (STD), high-fat (HF), high-fat 
supplemented with d-fagomine (HF + FG), high-fat supplemented with EPA/DHA (1:1) (HF + ω-3) or high-
fat supplemented with both d-fagomine and EPA/DHA (1:1) (HF + FG + ω-3) diet at the end of the study 
(week 24). Steatosis (A) and lobular inflammation. (B) Scores are presented as means with their standard error. 
Comparisons were made using one-way ANOVA followed by Tukey’s post-hoc test. *P < 0.05, **P < 0.01, 
***P < 0.001 vs STD; and #P < 0.05 vs HF.
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The increase of visceral adiposity in the HF group corresponded to the increase in the levels of leptin (Fig. 1C). 
The anorexigenic hormone leptin is mainly secreted by adipocytes and it is directly related to adipose tissue 
mass28. Plasma leptin concentration in the supplemented groups was statistically similar to those in the STD 
group (Fig. 1C). In agreement with our previous results13, fat accumulation and IR did not increase systemic OS 
as assessed by the levels of urine F2t-IsoPs (Fig. 1D). This result is also consistent with the observation that the 
generation of mitochondrial ROS occurs later than IR as a consequence of hyperglycemia, as observed in skeletal 
muscle of mice fed a high-fat high-sucrose diet29.
As there is mounting evidence that alterations in gut microbiota (dysbiosis) and intestinal barrier dysfunction 
may be the first steps leading to dietary fat-induced chronic systemic low-grade inflammation, visceral fat accu-
mulation and IR30, we checked the effects of d-fagomine, ω-3 PUFAs and their combination on relevant bacterial 
subgroups. At the phyla level, d-fagomine counteracted the high-fat diet-induced changes in the excreted popula-
tions of Bacteroidetes and Firmicutes (Fig. 3A,B). These results confirm our previous observations in WKY rats13. 
When administered alone, ω-3 PUFAs did not affect the changes in the excreted populations of Bacteroidetes and 
Firmicutes triggered by the high-fat diet (Fig. 3A,B). The combination of both supplements resulted in the highest 
Bacteroidetes/Firmicutes ratio in the cecum (Fig. 4C).
We next evaluated the changes in the populations of the putatively beneficial Lactobacilliales, Bifidobacteriales 
and the opportunist Enterobacteriales. d-Fagomine promoted the growth of Lactobacilliales and Bifidobacteriales 
(Fig. 3D,E, respectively) in agreement with our previous study in rats fed a standard diet14. Bifidobacteria have 
been shown to protect gut barrier function by preserving mucosal permeability and preventing translocation of 
pro-inflammatory pathogenic enterobacteria, such as E. coli31. The high-fat-induced state of systemic low-grade 
inflammation is probably initiated by bacterial components such as LPS which leak from an altered intestinal 
barrier32. d-Fagomine might be exerting an anti-inflammatory action by fostering gut colonization with bifido-
bacteria. d-Fagomine may also contribute a direct action against putatively harmful enterobacteria as it is capable 
of inhibiting adhesion of E. coli to the intestinal mucosa11. Neither the excess of fat nor the supplementation with 
ω-3 PUFAs had any significant effect on excreted lactobacilli or bifidobacteria.
It is known that part of the beneficial health effects of a well-balanced gut microbiota is mediated by SCFAs, 
which are products of microbial fermentation of dietary fiber33. The total excreted SCFAs were lower in the HF 
groups than in the STD group. This may be due to the fact that cellulose is almost the only source of fiber in the 
high-fat diet, which has been proved to yield amounts of SCFAs as low as those generated by fiber-free diets33. 
High-fiber low-fat diets are known to generate large amounts of fecal SCFAs (mainly acetic acid) compared to 
fiber-poor diets34. d-Fagomine partially counteracted the decrease of acetic acid and total SCFAs in rats fed the 
high-fat diet (Table 2). This effect could be explained by d-fagomine promoting the growth of SCFA-producing 
bacteria. We recently reported that d-fagomine stabilizes the populations of the genus Prevotella in the intestinal 
tract of SD rats fed a standard diet while reducing weight gain (Hereu, Nutrients, accepted). In the present study, 
d-fagomine showed some capacity to counteract the high-fat-induced reduction in the populations of Prevotella 
(Fig. 3G). As bacteria from this genus are capable of fermenting complex polysaccharides from the diet in a pro-
cess that is mechanistically linked to functional effects on glucose metabolism35, we hypothesize that d-fagomine 
might collaborate with dietary fiber in promoting the growth of beneficial bacteria. This effect is necessarily weak 
in the present case because the high-fat diet is low in fermentable fiber. The weight of the cecum is another indica-
tion of gut microbial activity, as rats supplemented with dietary fiber have been reported to have both cecal con-
tent and cecal tissue increased already after just two weeks of intervention36,37. Here, the cecal content in the HF 
group was significantly reduced with respect to the STD group while the cecal weight in the group supplemented 
with both d-fagomine and ω-3 PUFAs was significantly higher than that in the HF group and similar to that in the 
STD group. The present results with bacterial subpopulations and their fermentation products provide evidence 
that d-fagomine may contribute to the prevention of metabolic alterations by promoting balanced gut microbiota, 
whether it is combined with ω-3 PUFAs or not. The combination of supplements appears to be more effective than 
the individual supplementations in some cases (e.g. the Bacteroidetes:Firmicutes ratio and cecal content).
Liver histology yielded contradictory results, which may be consequence of activities downstream of gut 
microbial changes. The high-fat diet triggered lobular inflammation as expected13. d-Fagomine did not counteract 
this effect (Fig. 5B). The pro- and anti-inflammatory effects of the different agents in this experimental set-up may 
provide an explanation for these results. We previously showed that d-fagomine reduced the levels of fat-induced 
inflammatory markers in plasma and liver and we postulated that these effects might be attained by re-balancing 
the intestinal microbiota13. One possible explanation for the lack of effect of d-fagomine on SD rats fed a high-fat 
diet reported here is that the animals not supplemented with ω-3 PUFAs (STD, HF and HF + FG groups) were 
administered an equivalent dose of soybean oil to compensate for both the stress of probing and the excess of 
calories. Soybean oil, which is rich in the ω-6 PUFA LA, might have counteracted the putative microbiota-related 









HF ↑ ↑ ↑ ≈ ≈ ≈
HF + FG ↑ ≈ ≈ ≈ ↑ ↑
HF + ω-3 ↑ ≈ ↑ ≈ ≈ ≈
HF + FG + ω-3 ≈ ≈ ≈ ↑ ↑ ≈
Table 4. Qualitative summary of the main effects of diet and supplementations in SD rats compared to rats fed 
a standard diet. £Bacteroidetes: Firmicutes.
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by entering the ARA metabolic pathway (for a review see38). This will not happen in the case of ω-3 PUFA supple-
mentation, as EPA and DHA are converted into less inflammatory and even anti-inflammatory metabolites (for 
a review on the actions of ω-6 and ω-3 PUFAs see39). These events would occur downstream of the fat-induced 
microbial-triggered stimulation of inflammatory pathways. LA may have contributed to liver inflammation in the 
HF + FG group while EPA/DHA 1:1 might have reduced the pro-inflammatory effect of the saturated fats in the 
diet. The picture that emerges from this study, together with our previous reports, points towards a functional role 
for d-fagomine in the maintenance of eubiosis and the prevention of diet-induced IR reinforced by the action of 
ω-3 PUFAs via complementary mechanisms.
In conclusion, combined d-fagomine and EPA/DHA 1:1 attenuate high-fat-induced visceral fat, incipient IR, 
and liver inflammation; while increasing the cecal content, the Bacteroidetes:Firmicutes ratio and the gut pop-
ulation of Bifidobacteriales. The functional effects of the combination appear to be mainly those of d-fagomine 
complemented by those of EPA/DHA 1:1 (See Table 4 for a summary).
Received: 12 May 2019; Accepted: 16 October 2019;
Published: xx xx xxxx
References
 1. Hildebrandt, M. A. et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. 
Gastroenterology 137(1716–1724), e1711–1712 (2009).
 2. Portune, K. J., Benitez-Paez, A., Del Pulgar, E. M., Cerrudo, V. & Sanz, Y. Gut microbiota, diet, and obesity-related disorders-The 
good, the bad, and the future challenges. Mol Nutr Food Res 61 (2017).
 3. Turnbaugh, P. J. et al. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci 
Transl Med 1, 6–14 (2009).
 4. Weir, G. C. & Bonner-Weir, S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 53, S16–S21 
(2004).
 5. Janssen, A. W. & Kersten, S. Potential mediators linking gut bacteria to metabolic health: a critical view. J Physiol 595, 477–487 
(2017).
 6. David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563 (2014).
 7. Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Human gut microbes associated with obesity. Nature 444, 1022–1023 (2006).
 8. De Filippo, C. et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural 
Africa. Proc Natl Acad Sci USA 107, 14691–14696 (2010).
 9. Wu, G. D. et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 334, 105–108 (2011).
 10. Koyama, M. & Sakamura, S. The Structure of a new piperidine derivative from buckwheat seeds (Fagopyrum esculentum Moench). 
Agr Biol Chem 38, 1111–1112 (1974).
 11. Gómez, L. et al. D-Fagomine lowers postprandial blood glucose and modulates bacterial adhesion. Br J Nutr 107, 1739–1746 (2012).
 12. Ramos-Romero, S. et al. Effect of D-fagomine on excreted enterobacteria and weight gain in rats fed a high-fat high-sucrose diet. 
Obesity 22, 976–979 (2014).
 13. Ramos-Romero, S. et al. Functional effects of the buckwheat iminosugar D-fagomine on rats with diet-induced prediabetes. Mol 
Nutr Food Res, e1800373 (2018).
 14. Hereu, M., Ramos-Romero, S., García-González, N., Amézqueta, S. & Torres, J. L. Eubiotic effect of buckwheat D-fagomine in 
healthy rats. J Funct Foods 50, 120–126 (2018).
 15. Poudyal, H., Panchal, S. K., Diwan, V. & Brown, L. Omega-3 fatty acids and metabolic syndrome: Effects and emerging mechanisms 
of action. Prog Lipid Res 50, 372–387 (2011).
 16. Calder, P. C. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83, 1505s–1519s (2006).
 17. Mujico, J. R., Baccan, G. C., Gheorghe, A., Diaz, L. E. & Marcos, A. Changes in gut microbiota due to supplemented fatty acids in 
diet-induced obese mice. Br J Nutr 110, 711–720 (2013).
 18. Robertson, R. C. et al. Omega-3 polyunsaturated fatty acids critically regulate behaviour and gut microbiota development in 
adolescence and adulthood. Brain Behav Immun 59, 21–37 (2017).
 19. Ramos-Romero, S. et al. Effects of the combination of omega-3 PUFAs and proanthocyanidins on the gut microbiota of healthy rats. 
Food Res Int 97, 364–371 (2017).
 20. Marques, C. et al. High-fat diet-induced obesity Rat model: a comparison between Wistar and Sprague-Dawley Rat. Adipocyte 5, 
11–21 (2016).
 21. Molinar-Toribio, E. et al. Effect of n-3 PUFA supplementation at different EPA:DHA ratios on the spontaneously hypertensive obese 
rat model of the metabolic syndrome. Br J Nutr 113, 878–887 (2015).
 22. Pratap, A., Gupta, S. K., Kumar, J., Mehandi, S. & Pandey, V. R. In Breeding Oilseed Crops for Sustainable Production: Opportunities 
and Constraints (ed. Gupta, S. K.) Ch. 12, 293–315 (2016).
 23. Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and 
insulin concentrations in man. Diabetologia 28, 412–419 (1985).
 24. Molinar-Toribio, E. et al. D-Fagomine attenuates metabolic alterations induced by a high-energy-dense diet in rats. Food Funct 6, 
2614–2619 (2015).
 25. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29, e45 (2001).
 26. Schwiertz, A. et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity 18, 190–195 (2009).
 27. Taltavull, N. et al. Eicosapentaenoic acid/docosahexaenoic acid 1:1 ratio improves histological alterations in obese rats with 
metabolic syndrome. Lipids Health Dis 13, 31 (2014).
 28. Considine, R. V. et al. Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Engl J Med 334, 
292–295 (1996).
 29. Bonnard, C. et al. Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant 
mice. J Clin Invest 118, 789–800 (2008).
 30. Duan, Y. et al. Inflammatory links between high fat diets and diseases. Front Immunol 9, 2649 (2018).
 31. Caplan, M. S. et al. Bifidobacterial supplementation reduces the incidence of necrotizing enterocolitis in a neonatal rat model. 
Gastroenterology 117, 577–583 (1999).
 32. Sanmiguel, C., Gupta, A. & Mayer, E. A. Gut microbiome and obesity: A plausible explanation for obesity. Curr Obes Rep 4, 250–261 
(2015).
 33. den Besten, G. et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J 
Lipid Res 54, 2325–2340 (2013).
 34. Filippo, C. et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. 
Proc Natl Acad Sci USA 107 (2010).
1 2Scientific RepoRtS |         (2019) 9:16628  | https://doi.org/10.1038/s41598-019-52678-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
 35. Kovatcheva-Datchary, P. et al. Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of 
Prevotella. Cell Metab 22, 971–982 (2015).
 36. Jakobsdottir, G., Xu, J., Molin, G., Ahrne, S. & Nyman, M. High-fat diet reduces the formation of butyrate, but increases succinate, 
inflammation, liver fat and cholesterol in rats, while dietary fibre counteracts these effects. PLoS One 8, e80476 (2013).
 37. Dalby, M. J., Ross, A. W., Walker, A. W. & Morgan, P. J. Dietary uncoupling of gut microbiota and energy harvesting from obesity and 
glucose tolerance in mice. Cell Rep 21, 1521–1533 (2017).
 38. Naughton, S. S., Mathai, M. L., Hryciw, D. H. & McAinch, A. J. Linoleic acid and the pathogenesis of obesity. Prostaglandins Other 
Lipid Mediat 125, 90–99 (2016).
 39. Innes, J. K. & Calder, P. C. Omega-6 fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids 132, 41–48 (2018).
Acknowledgements
This work was supported by the Spanish Ministry of Economy, Industry and Competitiveness (Grant Numbers 
AGL2013-49079-C2-1, 2-R and AGL2017-83599-R, and graduate fellowship BES2014-068592 to M.H.). Technical 
advice from Inmaculada Fernández and english language revision by Christopher Evans are appreciated.
Author contributions
S.R.-R., M.R.N., I.M. and J.L.T. conceived and designed the research; M.H., S.R.-R., C.B. and L.M. contributed and 
performed the animal intervention, the biometric determinations, the evaluation of glycemic status and the qRT-
PCR experiments; L.A. performed the histology; M.H. and S.A. performed the IsoP and SCFA measurements; 
M.H., S.R.-R., B.M.-P. and L.M. analysed the data and M.H., S.R.-R. and J.L.T. wrote the paper.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-019-52678-5.
Correspondence and requests for materials should be addressed to S.R.-R.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
